Status:
COMPLETED
A Randomized Clinical Trial of Metoprolol in Participants With Mitral Regurgitation.
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
AstraZeneca
Conditions:
Heart Valve Diseases
Eligibility:
All Genders
21+ years
Phase:
PHASE4
Brief Summary
Mitral valve regurgitation (leakage of the mitral valve of the heart) is frequent and currently there is no specific medical therapy. Mitral regurgitation is a slowly progressive disease that frequent...
Detailed Description
Background: Mitral regurgitation (MR) is frequent and its prevalence is increasing with aging of the population. Organic MR, due to primary valvular lesions has severe consequences determined by its d...
Eligibility Criteria
Inclusion
- Inclusion criteria: Patients a) 21 years old or older, with b) MR observed with color flow imaging, c) due to organic mitral valve disease demonstrated by Echocardiography (not normal valve as in functional or ischemic MR), c) isolated (no valve disease other than functional tricuspid regurgitation by Doppler-Echocardiography), d) pure (no mitral stenosis by Doppler-Echocardiography), e) quantifiable by Doppler-Echocardiography, f) of degree \* moderate, defined as RVol \* 30 mL/beat, g) occurring on native valves, h) with echocardiographic imaging allowing assessment of LA and LV, and i) asymptomatic (or mildly symptomatic but not considered as candidates for immediate surgery by their attending physician).
Exclusion
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00166400
Start Date
July 1 2004
End Date
July 1 2007
Last Update
July 24 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905